GlassScriptPhysician profile
Shaoxian Qin
NPI 1831630813
$6,878.97
in general payments reported to CMS, 2019-2025
24 companies · $973 in 2025
The $973 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $985 · 2022: $1,307 · 2023: $1,650 · 2024: $1,964 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,521 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.05 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $868.55 | 2021-2024 | Breztri, Farxiga, Lokelma |
| Novo Nordisk INC | $794.79 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $701.45 | 2021-2025 | Krystexxa, Evenity, Repatha |
| Gilead Sciences, INC. | $535.73 | 2021-2025 | Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $460.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $450.95 | 2021-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $448.79 | 2021-2025 | Mounjaro, Zepbound |
| Scilex Pharmaceuticals INC. | $350.21 | 2022-2025 | Ztlido |
| Merck Sharp & Dohme LLC | $240.57 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Agios Pharmaceuticals, INC. | $206.36 | 2024-2025 | Pyrukynd |
| Dynavax Technologies Corporation | $202.18 | 2024-2025 | Heplisav-B |
| Abbvie INC. | $190.03 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $188.50 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.93 | 2021-2025 | Jardiance |
| Stryker Corporation | $173.45 | 2024 | Omnicurve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $170.81 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $149.08 | 2024 | Reblozyl |
| Viatris Specialty LLC | $122.39 | 2025 | Yupelri |
| Astellas Pharma US INC | $106.46 | 2024-2025 | Veozah |
| Edwards Lifesciences Corporation | $88.17 | 2024 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $85.19 | 2021 | |
| Mallinckrodt Hospital Products INC. | $75.27 | 2023 | Acthar |
| Xeris Pharmaceuticals, INC. | $58.13 | 2023-2024 | Gvoke Hypopen |
| Radius Health, INC. | $27.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaoxian Qin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.